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Abstract
Background: Cancer is caused by genetic abnormalities, such as mutations of oncogenes or
tumor suppressor genes, which alter downstream signal transduction pathways and protein-
protein interactions. Comparisons of the interactions of proteins in cancerous and normal cells can
shed light on the mechanisms of carcinogenesis.
Results: We constructed initial networks of protein-protein interactions involved in the apoptosis
of cancerous and normal cells by use of two human yeast two-hybrid data sets and four online
databases. Next, we applied a nonlinear stochastic model, maximum likelihood parameter
estimation, and Akaike Information Criteria (AIC) to eliminate false-positive protein-protein
interactions in our initial protein interaction networks by use of microarray data. Comparisons of
the networks of apoptosis in HeLa (human cervical carcinoma) cells and in normal primary lung
fibroblasts provided insight into the mechanism of apoptosis and allowed identification of potential
drug targets. The potential targets include BCL2, caspase-3 and TP53. Our comparison of
cancerous and normal cells also allowed derivation of several party hubs and date hubs in the
human protein-protein interaction networks involved in caspase activation.
Conclusion: Our method allows identification of cancer-perturbed protein-protein interactions
involved in apoptosis and identification of potential molecular targets for development of anti-
cancer drugs.
Background
Study of interactome, the entire set of molecular interac-
tions within cells, has provided many insights into the eti-
ology and regulation of cancer [1,2]. Tumorigenesis is a
multi-step process caused by genetic alterations that drive
the progressive transformation of normal cells into malig-
nant cells. At the molecular level, genetic mutations,
translocations, amplifications, deletions, and viral gene
insertions can alter translated proteins and thereby dis-
rupt signal transduction pathways and protein-protein
interactions that are essential for apoptosis and other
important cellular processes [3]. Inactivation of pro-apop-
totic proteins or up-regulation of anti-apoptotic proteins
results in unchecked growth of cells and ultimately to can-
cer [4]. From a systems biology perspective, cancer is
mainly caused by malfunctions of perturbed protein inter-
action networks in the cell [5,6].
Apoptosis is necessary for normal human development
and survival, in that cells must die in order to prevent
uncontrolled growth [7]. Apoptosis requires activation of
multiple pathways via regulated protein-protein interac-
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tions [8]. Apoptosis is mediated by an intrinsic pathway,
which is triggered by "death stimuli" (e.g., DNA damage,
oncogene activation, among others) within a cell, or by an
extrinsic pathway, which is initiated by binding of an
extracellular "death ligand". The extrinsic pathway can
link to the intrinsic pathway, which then triggers the
release of mitochondria proteins via protein-protein inter-
actions [4,8,9]. During apoptosis, several proteins are
released from the intermembrane space of the mitochon-
dria into the cytoplasm and these proteins activate initia-
tor caspases and trigger a series of protein-protein
interactions in the caspase cascade. Evading apoptosis is
one of the six acquired capabilities of cancer cells [3], and
anticancer treatment using cytotoxic drugs is considered
to mediate cell death by activating key elements of the
apoptosis program and the cellular stress response [10].
Comprehensive knowledge of protein-protein interac-
tions provides a framework for understanding the biology
of cancer as an integrated system [11].
Most gene products mediate their functions within com-
plex networks of interconnected macromolecules, form-
ing a dynamic topological interactome [11,12]. High
throughput two-hybrid experiments [13,14] and several
online interactome databases, such as BIND [15], HPRD
[16], Intact [17], and Himap [18], allow analysis of the
global topologies of human protein-protein interactions.
BIND [15] is a database designed to store full descriptions
of interactions, molecular complexes and pathways.
HPRD [16] provides detailed data including protein
sequences, localization, domains, and motifs, and thou-
sands of protein-protein interactions, with other data.
Intact [17] contains an enrichment of protein-protein
interactions, related literature, and experimental detail.
Himap [18] combines two datasets of yeast-two-hybrid
experiments [13,14] to form a human protein reference
database [16], with references to functions and predic-
tions.
However, experimental and database approaches often
yield "false-positives" [19]. For example, yeast two-hybrid
experiments based on transactivation of reporter genes
require the presence of auto-activators, where the bait acti-
vates gene expression in the absence of any prey [11]. The
yeast two-hybrid technique can yield false-positives (spu-
rious interactions detected because of the high-through-
put nature of the screening process), and false-negatives
(undetected interactions) [19,20]. Computational meth-
ods can refine protein-protein interaction networks and
result in fewer false-positives [21,22]. Because of the com-
plex nature of interactomes, such as that observed in the
apoptosome complex during caspase formation [7,8,23],
a nonlinear mathematical model provides better charac-
terization than a linear model [24,25]. In addition, a sto-
chastic model allows consideration of intrinsic and
extrinsic molecular "noise" that causes stochastic varia-
tions in transcription and translation [24]. In this paper,
we describe a nonlinear stochastic model that character-
izes dynamic protein-protein interaction networks of
apoptosis in cancerous and normal cells.
In this study, we built an initial protein-protein interac-
tion network based on two human yeast two-hybrid data
sets [13,14] and four online interactome databases such as
BIND [15], HPRD [16], Intact [17], and Himap [18]. Next,
we constructed a nonlinear stochastic model of dynamic
protein-protein interactions to eliminate false-positives
from the network by applying a statistical method (Akaike
Information Criterion, AIC) to the high-throughput pro-
tein interaction data. We regard all proteins in an organ-
ism as a large dynamic interaction system. Protein-protein
interactions are considered as nonlinear stochastic proc-
esses with several expression profiles of interactive protein
partners as input, and the expression profile of a target
protein as output. Because of random noise and uncer-
tainties during experiments, we describe protein-protein
interactions with stochastic discrete nonlinear dynamic
equations. We considered linear individual (or binary)
protein interactions and nonlinear cooperative protein
complex interactions, but not DNA-protein or metabolite
interactions. First, we constructed protein-protein interac-
tion networks of apoptosis in HeLa (human cervical carci-
noma) cells and normal primary human lung fibroblasts
based on microarray data [26]. Next, we obtained the can-
cer-perturbed protein-protein interaction network by
comparison of apoptosis in normal cells via gain-of-func-
tion and loss-of-function networks. Because current drugs
designed to induce apoptosis kill cancer cells as well as
normal cells, these cancer-perturbed protein-protein
interaction networks allow identification of potential
selective targets of apoptosis-promoting drugs [5].
Results and Discussion
Construction of the cancer-perturbed protein-protein 
interaction network of apoptosis
Initially, we selected proteins that are known to have roles
in apoptosis and considered them as the "core nodes" of
our network. These included BAX (BCL2-associated X pro-
tein), BCL2 (B-cell CLL/lymphoma 2), BID (BH3 interact-
ing domain death agonist), CASP3 (caspase-3), BIRC4
(baculoviral IAP repeat-containing 4), CASP9 (caspase-9),
CYCS (cytochrome c, somatic), and DIABLO (diablo
homolog, Drosophila). Networks, such as ours, that are
developed from initially selected genes or proteins as the
core nodes are referred to as "BRAC-centered networks"
[27]. Our initial apoptosis network contained 207 protein
nodes and 841 protein-protein interaction edges.
From equations (1) to (13) (see "Methods"), we calcu-
lated each protein interaction twice, with each partnerBMC Systems Biology 2008, 2:56 http://www.biomedcentral.com/1752-0509/2/56
Page 3 of 17
(page number not for citation purposes)
Global protein-protein interactions of apoptosis in cancerous and normal cells Figure 1
Global protein-protein interactions of apoptosis in cancerous and normal cells. (A) Apoptotic protein-protein inter-
action network in HeLa cells, showing 183 nodes and 552 edges. (B) Apoptotic protein-protein interaction network in normal 
primary lung fibroblasts, showing 175 nodes and 547 edges. Each interaction was calculated twice and only interactions with 
two '1' scores after AIC evaluation was considered 'true' interactions (see Supplementary Table 1 for detailed information). All 
protein-protein interaction networks in this study were constructed with Osprey version 1.2.0.
A
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considered as the target protein. The final results are
shown in Figure 1 and Supplementary Table 1 (see "Addi-
tional file 1"). Figure 1 illustrates the individual and coop-
erative protein-protein interaction networks of apoptosis
in cancerous cells (183 nodes and 552 edges) and normal
cells (175 nodes and 547 edges). These networks are easily
modeled by undirected graphs, where the nodes are pro-
teins and two nodes are connected by an undirected edge
if the corresponding proteins bind one another [28].
Supplementary Table 1 compares the networks of apopto-
sis in HeLa cells and normal primary human lung fibrob-
lasts. These data show, for example, that BAX and PEG3
interact in both cell types, that BAX and CCND1 interact
in neither cell type, that BAX and RARG interact in normal
cells but not in cancerous cells, and that BAX and BCL2L1
interact in cancerous cells but not in normal cells. In order
to identify drug targets for anti-cancer drugs, it is impor-
tant to identify cancer-perturbed protein-protein interac-
tion networks to identify drug targets to kill cancer cells
[3]. If an interaction is absent in normal cells, but present
in cancer cells, we call it "gain-of-function"; if an interac-
tion is present in normal cells but not in cancerous cells,
we term it "loss-of-function". For the 841 interactions that
we identified, we classified 157 (18.7%) as "gain-of-func-
tion" and 162 (19.3%) as "loss-of-function" (Figs 2A and
2B). This network analysis identified 38%
(18.7%+19.3%) of all protein-protein interactions during
apoptosis as potential drug targets.
Figure 2 shows nodes that are colored according to pro-
tein family, as annotated by the Gene Ontology (GO)
hierarchy, and illustrates gain- and loss-of-function inter-
actions derived from Supplementary Tables 2 and 3 (see
'Additional file 2' and 'Additional file 3'). Proteins are
listed with Gene Ontology (GO) annotations according to
the number of perturbed interactions. All protein candi-
dates with more than five degrees of perturbations are
shown, to illustrate the number of links with perturbed
nodes. Gain-of-function proteins with more than five
degrees of perturbations in Figure 2A include BCL2,
CASP3, TP53, BCL2L1, PRKCD, MAPK3, NFKB1, BIRC3,
CCND1, and PCNA. Loss-of-function proteins with more
than five degrees of perturbations in Figure 2B include
BCL2, BAX, CASP3, CDKN1A, TP53, BCL2L1, TNF,
CASP9, EGFR, MAPK1, APC, TNFRSF6, BAK1, MYC,
CFLAR, and APP (see Supplementary Tables 2 and 3). The
BCL2 protein has the highest degree of perturbations (18
and 17) in cancerous and normal cells, respectively.
In order to confirm the topology of our networks (Fig. 2),
we calculated the false-positive and false-negative rates for
the 86 BCL2-interacting proteins in normal cells by use of
the HPRD (Human Protein Reference Database) [16] and
literature review (see the representative example in Sup-
plementary Table 4 from 'Additional file 4'). After refine-
ment by our algorithms, we reduced the false-positive rate
to 1.16%. However, the false-negative rate remained at
41.87%, indicating incomplete construction of the net-
work from current experiments and databases. Therefore,
compensation by k (see equation (1) in "Methods") is
important for estimation of model parameters.
Cancer-perturbed apoptosis mechanism at the systems 
level
In many cancers, pro-apoptotic proteins are inactivated or
anti-apoptotic proteins are upregulated, leading to
unchecked growth and an inability to respond to cellular
stresses [4]. These gain- and loss-of-function mutations
lead to aberrations in protein-protein interaction net-
works. An integration of interactome data and genomic
data can provide a clearer understanding of the functional
relationships that underlie apoptosis and other biological
processes [11,21]. The results of our investigation of the
apoptosis mechanism at the systems level and the elucida-
tion of cancer-perturbed protein-protein interaction net-
work topology are depicted in Figs. 2A and 2B.
Extrinsic pathway, intrinsic pathway and crosstalk
Members of the death receptor superfamily trigger the
extrinsic apoptosis pathway upon recruit of caspase-8
through the adaptor protein FAS (TNFRSF6)-associated
death domain (FADD) [7]. Binding of a "death ligand" to
a receptor triggers formation of a signaling complex that
activates caspase-8 or caspase-10, which then activates
caspase-3, and finally promotes cell death [23]. Extracel-
lular and intracellular stress triggers the intrinsic apoptosis
pathway (mitochondria pathway), which involves activa-
tion of pro-apoptotic members of the Bcl-2 family [8].
Bid, a pro-apoptotic member of the Bcl-2 family, allows
crosstalk between the extrinsic and intrinsic pathways.
The three subfamilies of Bcl-2-related proteins are the
anti-apoptotic proteins (e.g., BCL2 and BCL2L1), the pro-
apoptotic multi-domain proteins (e.g., BAX and BAK),
and pro-apoptotic BH3-only proteins (e.g., BID and BIM)
[9,29].
Of the 19 Bcl-2 proteins or regulators (see "goProcess" in
Supplementary Tables 2 and 3), 11 are present in Figs. 2A
and 2B (BAD, BAG4, BAK1, BAX, BCL2, BCL2A1, BCL2L1,
BCL2L11, BID, HRK, and MCL1), 4 are present in Fig. 2A
alone (BAG2, BCL2L10, BCL6, and BIK) and 4 are present
in Fig. 2B alone (BAG1, BAG3, BAG5, and BCL2L14). This
indicates that there is not a simple dichotomy between
gain-of-function and loss-of-function proteins in the can-
cer interactome. For example, BAX has 4 gain-of-function
interactions with BCL2L1, TP53, MFN2, and BCL2L10 but
it also has 13 loss-of-function interactions with RARG,
MCL1, BCL2A1, CDKN1A, MAPK11, APP, APC, CASP2,
PRKCE, RNF36, ADPRT, TGFBR2, and TNFRSF5 (Fig. 2).BMC Systems Biology 2008, 2:56 http://www.biomedcentral.com/1752-0509/2/56
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Cancer-perturbed protein-protein interactions in the apoptosis network Figure 2
Cancer-perturbed protein-protein interactions in the apoptosis network. (A) 'Gain-of-function' network, showing 
140 nodes and 157 edges. (B) 'Loss-of-function' network, showing 126 nodes and 162 edges. Colors of nodes represent Gene 
Ontology annotations. Supplementary Tables 2 and 3 list proteins with detailed Gene Ontology annotations, with ranking 
according to the degree of perturbation.
A
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Caspases family and caspases regulators
The apoptosis death signal is activated via a series of pro-
tease caspases (initiator caspases-2, -8, -9, and -10, and
effector caspases-3, -6, and -7) which require activation by
proteolysis [8,9]. With the exception of CASP6, which is
present only in the gain-of-function network, the caspases
(including CASP1, CASP2, CASP4, CASP7, CASP9 and
CASP10) occur in the gain-of-function and loss-of-func-
tion networks. Seven caspase activators, inhibitors, and
regulators (including BAX, TP53, CFLAR, CYCS, CARD4,
BIRC4, and DIABLO) are present in both networks (Figs.
2A and 2B). This reveals the different roles of caspase reg-
ulators in cancerous and normal cells.
Regulation of apoptosis at the systems level
Besides Bcl-2 and caspases, proteins involved in apoptosis
regulation include BIRC3, PTEN, CARD12, MAP3K7,
DEDD2, MITF, MALT1, BCL6, NALP1, CRADD, RTN4,
PSEN1, IGFBP3, BNIP3L, RARG, CFLAR, TRAF3, TRAF1,
MCL1, CARD4, TRAF6, VEGF, BIRC2, FGFR1, PEA15,
DEDD, MMP9, HRK, and TP53 (Figs. 2A and 2B). Thus,
we have identified 29 proteins, in addition to members of
the Bcl-2 and caspase families, that regulate apoptosis at
the systems level.
Apoptosis and cell cycle regulation
Proteins generally function as components of complexes
that contain other macromolecules, to carry out specific
biological processes. Networks of interactions connect dif-
ferent cellular processes [11]. We have identified 30 pro-
teins in the protein-protein interaction network of
apoptosis that also participate in cell-cycle regulation.
These are PTEN, CDC6, MFN2, PKMYT1, DCC, and E2F1
in Fig. 2A, and BIRC5, NRAS, MKI67, E1F1, PPP3CA,
BCL2, TP53, MAPK3, CCND1, PCNA, EGFR, MAPK1,
VEGF, BAX, CDKN1A, TGFB1, APC, MSH2, APP, KRAS2,
HRAS, CDKN1B, CDKN2A, and PML in Fig. 2B.
Although Figs. 2A and 2B describe the perturbation of
apoptosis at the systems level, most proteins with high
degree of perturbation (Fig. 2A) are also included in Fig.
2B. In other words, it is not possible to uniquely describe
protein hubs as "gain-of-function" or "loss-of-function"
hubs. Therefore, we summarized the degree of perturba-
tion (Supplementary Tables 2 and 3) to identify the per-
turbed protein hubs in the network of cancer cells. After
identifying targeted proteins as inhibitors or activators, it
is necessary to study how a drug target is wired into the
control circuitry of a complex cellular network [30]. Next,
we show a flow chart for identification and prediction of
apoptosis drug targets in cancer drug discovery.
Prediction of apoptosis drug targets using cancer-
perturbed networks of apoptosis
Systems-based drug design is a major application of sys-
tems biology [5,25,31]. This method constructs disease-
perturbed protein-protein interaction networks and iden-
tifies potential drug targets by comparison of the networks
of normal and abnormal cells. This contrasts with the tra-
ditional approach, which reduces cellular processes to
their individual components or signal transduction path-
ways and targets a specific molecule or signaling pathway.
A limitation of this traditional approach is that a single
molecule or pathway does not adequately describe most
biological systems, including those affected in cancer [25].
By comparisons of the protein-protein interaction net-
works of normal and cancerous cells derived from micro-
array data, we can identify potential drug targets through
a systems-based approach (Fig. 3).
Flow chart for identification of potential drug targets in the  cancer-perturbed network using microarray data Figure 3
Flow chart for identification of potential drug targets 
in the cancer-perturbed network using microarray 
data.
Use nonlinear stochastic model
& Akaike Information Criteria (AIC)
to modify initial protein-protein
interaction networks
Derive gain- and loss-of-function 
networks to identify protein hubs with 
high degree of perturbation
Microarray data set 
of cancerous cells
Protein-protein 
interaction networks
of cancerous cells
Drug target discovery
Construct initial protein-protein 
interaction networks from large-scale 
experiments and databases
Protein-protein 
interaction networks
of normal cells
Microarray data set 
of normal cellsBMC Systems Biology 2008, 2:56 http://www.biomedcentral.com/1752-0509/2/56
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Thus, we built initial protein-protein interaction networks
from large-scale experiments and databases, and then
employed each microarray data set of HeLa cells and pri-
mary lung fibroblasts to modify these networks. For net-
work modification, we used a nonlinear stochastic model
and the Akaike Information Criterion (AIC). We next
compared the networks of cancerous and normal cells,
derived gain-of-function and loss-of-function networks,
and identified protein hubs with high degree of perturba-
tion as potential drug targets.
Scale-free networks are extremely sensitive to removal of
targeted hubs (i.e., attack vulnerability [11,12,32]), so we
summed the degree of perturbation (i.e., connectivity) of
each node in the cancer-perturbed network (Supplemen-
tary Tables 2 and 3) to obtain these perturbed hubs. Pro-
teins with sum of degree of perturbation ≥ 8 (Table 1)
differentiate the cancerous and normal interactomes and
are potential drug targets [6,25]. We classified the 17
potential drug targets (Table 1) into six categories: (i)
Intrinsic pathway: BCL2, BAX, BCL2L1, BID, and CYCS;
(ii) Extrinsic pathway: TNF and TNFRSF6; (iii) Common
pathway: CASP3 and CASP9; (iv) Apoptosis regulators:
TP53, MYC, CFLAR, and EGFR; (v) Stress-induced signal-
ing: MAPK1 and MAPK3; and (vi) Others: CDKN1A and
CCND1. Our results indicate that most proteins interact
with few partners, whereas hubs interact with many part-
ners, consistent with current views on interactome net-
works with a scale-free or power law degree distribution
[11].
Intrinsic pathway: BCL2, BAX, BCL2L1, and CYCS
Defective apoptosis in human cancers often results from
over-expression or inhibition of BCL2 proteins. These
proteins regulate mitochondrial permeability by inhibit-
ing (e.g., BCL2 and BCL2L1) or promoting (e.g., BAX and
BID) release of cytochrome c (CYCS) [33]. BCL2 and sev-
eral anti-apoptotic relatives, such as BCL2L1, associate
with the mitochondrial outer membrane and the endo-
plasmic reticulum nuclear membrane and maintain the
integrity of these membranes. Initiation of apoptosis
requires pro-apoptotic family members that closely
resemble BCL2 and distantly related proteins that are
related only by the small BH3 protein-interaction domain
[29]. In our results, proteins with gain-of-function interac-
tions with BCL2 include CCND1, BAD, MCL1, MAPK3,
ADM, KITLG, EGFR, BAG2, PKMYT1, TP53, PCNA, MITF,
ABCB1, BCL6, ZNF384, HRK, PPP2R5A, and VEGF (Sup-
plementary Table 2). Proteins with loss-of-function inter-
actions with BCL2 include CDKN1A, TNF, WT1, BAG4,
BCL2L14, DEK, GRN, RAF1, BLK, BAG5, CAPN2, GHR,
CDKN1B, RTN4, BNIP3L, MAP3K1, and CLC (Supple-
mentary Table 3). We predict BCL2 to be the best poten-
tial drug target because this protein best differentiates
protein-protein interaction networks of HeLa and normal
cells [5,25].
Our analysis agrees with the conclusions of previous stud-
ies which showed that BCL2 protein family members are
good targets for cancer therapy. Drugs that target BCL2
include Genasense [4,34] and ABT-737 [35]. The activa-
tion of Bax can be induced by gene therapy through deliv-
ery of Bax vectors, and this approach has been successful
in inducing apoptosis in cancer cell lines [4]. Antisense
BCL2L1 (BCL-xL) downregulates the expression of BCL2
and BCL2L1, induces apoptosis, and inhibits growth of
several tumor types in vitro and in vivo [34]. Unfortunately,
targeting of BCL-2 also causes adverse effects, presumably
Table 1: 17 potential drug targets ranked by sum of degree of perturbation ≥ 8 in Supplementary Tables 2 and 3
Protein targets Sum of degree of perturbation Agents Literature review
BCL2 35 G3139 (Genasense), ABT-737 [4,29,33-36,38]
CASP3 22 Synthetic activators of caspases/Apoptin/IAP targets surviving [33,34,36]
BAX 17 Gene therapy through Bax vectors [34]
TP53 17 ONY-015/INGN201/MDM2 inhibitors [4,34,38,39]
BCL2L1 13 Antisense BCL-xL [34]
CDKN1A 13 [43]
TNF 10 [4,34]
EGFR 9 Trastuzumab (Herceptin) [34]
MAPK1 9 CI-1040/PD0325901/ARRY-142886 [41,42]
MAPK3 9 CI-1040/PD0325901/ARRY-142886 [41,42]
MYC 9 Bortezomib (Proteosome Inhibitors) [40]
BID 8 [34]
CASP9 8 Caspases activators/Apoptin/surviving [33,34,36]
CCND1 8 [44]
CFLAR 8 [23]
CYCS 8 [37,38]
TNFRSF6 8 [34]BMC Systems Biology 2008, 2:56 http://www.biomedcentral.com/1752-0509/2/56
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because many normal cells depend on proteins in the
BCL-2 family to maintain normal mitochondrial func-
tion. Difficulty in using BCL-2 antisense DNA or RNA as a
delivery system is a problem with Genasense [36]. Cyto-
chrome c, once released into the cytosol, interacts with
Apaf-1 and this leads to activation of caspase-9 proen-
zymes [34]. The chief function of BCL-2 proteins is to reg-
ulate the release of cytochrome c  from mitochondria.
Thus, targeting CYCS or Apaf-1 would also be expected to
cause severe adverse effects [37,38].
Extrinsic pathway and crosstalk: TNF, TNFRSF6, and BID
The extrinsic pathway activated by death receptors, such as
Fas (TNFRSF6/APO-1/CD95) and other TNF receptor
family members, allows apoptosis to maintain normal tis-
sue homeostasis [7]. Although death receptors of the TNF
superfamily members are potential targets for anti-cancer
drugs, toxic side effects have been observed that place lim-
its on their therapeutic use [4]. TNF and Fas (TNFRSF6)
were also found to activate nonspecific TNF receptors
resulting in extensive ischemic and hemorrhagic lesions in
several tissues leading to septic shock and fulminating
hepatic failure in animal models [34].
A more promising approach involves targeting the TRAIL
(TNF-Related Apoptosis Inducing Ligand) receptors
[4,7,34]. Activation of the TRAIL death receptor can kill
cancerous cells but not normal cells, whereas monoclonal
antibodies against TRAIL and recombinant TRAIL ligand
can cause TRAIL resistance [36]. Thus, administration of
such a drug might cause tumors to develop resistance, or
cause the death of normal cells. BID, a pro-apoptotic Bcl-
2 family member, provides crosstalk and integration
between the death-receptor and mitochondrial pathways
[8,9]. Targeting BID, however, is rarely discussed,
although such work has potential for use in combined
therapy [34].
Common pathway: CASP3 and CASP9
Caspases are the central components of the apoptotic
response network. An effector caspase (e.g., caspase-3) is
activated by an initiator caspase (e.g., caspase-9) and the
initiator caspase is activated via other protein-protein
interactions [8,9]. Targeting inhibitors of caspases could
potentially cause apoptosis of cancerous cells. Synthetic
activators of caspases include Apoptin and IAP [33,34].
Caspase-3 and -9 are subject to inhibition by IAPs such as
Livin [9]. Like BCL-2 inhibitors, XIAP inhibitors must
block protein-protein interactions. When released from
mitochondria, Smac binds XIAP and inactivates it, trigger-
ing apoptosis [36].
Apoptosis regulators: TP53, MYC, CFLAR, and EGFR
One of the most dramatic responses to p53 is induction of
apoptosis and regulation via the intrinsic pathway [39].
Drug trials that target p53 include gene therapy involving
ONYX-015 and INGN201 and antisense therapy that tar-
gets a protein controlling p53 activity by Nutlins which
blocks p53/MDM2 interaction [4,34]. The proto-onco-
gene c-MYC encodes a transcription factor that is impli-
cated in various cellular processes, including cell growth,
proliferation, loss of differentiation, and apoptosis. The
induction of cell-cycle entry sensitizes the cell to apopto-
sis, so that cell-proliferation and apoptotic pathways are
coupled [40]. CFLAR (c-FLIP) regulates caspase-8 and
FADD-like apoptosis. Whereas CFLAR blocks the activa-
tion of the initiator caspase-8, XIAP can block the initia-
tion phase (by inhibition of caspase-9) and the execution
phase (by blocking caspase-3 and caspase-7) [23]. Some
agents, for example, agent ZD1839 as an EGFR (epidermal
growth factor receptor) inhibitor, do not primarily target
apoptosis, but indirectly modulate apoptosis [34].
Stress-induced signaling and others: MAPK1, MAPK3, CDKN1A, and 
CCND1
Proteins of the MAPK (mitogen-activated protein kinase)
family are crucial in many signaling pathways [41]. Three
MEK (MAPK kinase) inhibitors, CI-1040, PD0325901,
and ARRY-142886, are currently in clinical trials for treat-
ment of various cancers [42]. Although some drugs target
MAPKs, MAPK1 (ERK or p38), and MAPK3 (ERK1) are
not the main drug targets in the apoptotic pathway [34].
CDKN1A (p21) (cyclin-dependent kinase inhibitor-1)
plays a role in cell cycle arrest and induction of apoptosis.
The activities of cyclin D- and cyclin E-dependent kinases
are linked through the Cip/Kip family of Cdk inhibitors,
including p27 and p21 [43]. CCND1 is cyclin D1 in the
G1/S transition of the cell cycle, and is controlled by the
tumor suppressor gene RB through cdk-cyclin D com-
plexes [44].
Prediction of additional drug targets by decreasing the degree of 
perturbation
In addition to identifying several apoptosis drug targets
that have already been identified by other studies, we
applied our method to predict additional drug targets by
decreasing the perturbation threshold. Thus, if we reduce
the sum of degree of perturbation to 7, we predict the fol-
lowing additional targets: BAK1, CASP2, BCL2A1, IGF1,
PRKCD, NFKB1, and PCNA. NFKB1 has both anti- and
pro-apoptotic functions that are determined by the nature
of the death stimulus. The drug PS11445 targets the
NFKB1 inhibitor IKKβ [34] but the other proteins have
not previously been considered as drug targets.
Prediction of new GO annotations of the four proteins: CDKN1A, 
CCND, PCNA, and PRKCD
If we consider all 24 proteins with sum of degree of per-
turbation ≥ 7, four proteins (CDKN1A, CCND1, PRKCD
and PCNA) are also considered to have a role in apopto-BMC Systems Biology 2008, 2:56 http://www.biomedcentral.com/1752-0509/2/56
Page 9 of 17
(page number not for citation purposes)
sis. If the function of any one protein in a network is
known, identification of its interacting partners allows
prediction of their functions [11]. However, two of these
proteins (PCNA and PRKCD) are known to have a role in
DNA damage-induced apoptosis. PCNA (Proliferating
Cell Nuclear Antigen) is ubiquitinated and involved in
RAD6-dependent DNA repair in response to DNA dam-
age. PRKCD (protein kinase C, delta) is also associated
with DNA damage-induced apoptosis [45], whereas gene
ontology annotations of PRKCD do not include apoptosis
(Supplementary Tables 2 and 3).
Although other methods (such as identification of protein
domains) allow prediction of protein-protein interactions
in different organisms [46-48], these methods do not
allow identification of potential drug targets. Our method
provides efficient and precise prediction of anti-cancer
drug targets and also specifies these target proteins with
detailed Gene Ontology annotations. This will help
researchers identify additional drug targets by examina-
tion of other cellular mechanisms involved in cancer. Net-
work modeling has been used to identify genes
potentially associated with breast cancer in a BRAC-cen-
tered network [27]. However, there are very few time-
series microarray databases for cancerous and normal
cells, so it is difficult to use our method to compare pro-
tein hubs for different types of cancer. Moreover, our
method does not address the potential adverse effects of
targeting a specific protein and the problem of drug deliv-
ery. We expect that more genomic time-series microarray
experiments and clinical research will address these limi-
tations in the future.
Caspase activation through static and dynamic hubs
Static network topology is not sufficient to define func-
tion, and incorporating time-dependent expression data is
important for understanding pathway function [20]. A
number of computational approaches have been pro-
posed for prediction of protein-protein interactions, such
as domain-domain interactions [46], the confidence score
resulting from sequence similarity and number of edges
[2], and integration of genomic data sets [49]. A nonlinear
stochastic model can depict protein-protein interaction
networks at different times by using linear binary interac-
tions and nonlinear protein complex relationships. Previ-
ous studies have used linear stochastic models to describe
the multiple feedback loops of p53 [50], but nonlinear
effects cannot be depicted by this method. Our method
also illustrates the dynamic behavior of protein-protein
interaction networks, which cannot be examined by prob-
abilistic methods of data integration [49].
Networks consist of party hubs (static hubs) and date
hubs (dynamic hubs). Party hubs are found in static com-
plexes with most of their partners present at the same
time, whereas date hubs bind their interaction partners at
different times or locations [12,51]. To further investigate
dynamic apoptotic properties in human cells, we consid-
ered caspases as protein hubs in our dynamic nonlinear
stochastic protein-protein models (Figs. 4A–D, Supple-
mentary Tables 5 and 6 in 'Additional file 5' and 'Addi-
tional file 6'). In order to identify party hubs and date
hubs, we first summed the degree of perturbation of each
protein as 'plus degree of perturbation' and then sub-
tracted the degree of perturbation of each protein as
'minus degree of perturbation' at two time periods in can-
cerous and normal cells. If the plus degree of perturbation
of one protein was ≥ 20, we defined this protein as a 'hub'.
If the minus degree of perturbation of the hub was ≤ 3, we
defined the hub as a party hub (static hub). If the minus
degree of perturbation of the hub was >3, we defined the
hub as a date hub.
Figures 4A–D illustrate the time-dependence of the net-
works, where bold lines represent distinct interactions at
different times. Caspase signaling results in time-variant
protein-protein interactions, and dynamic modeling
allows specification of the time-dependent interactome.
In cancerous cells, the date hubs include BIRC2, CASP2,
and CASP3, and the party hubs include TP53, TNF,
BIRC3, BAX, CASP1, and CASP9. In normal cells, date
hubs include CASP3 and CASP9 and party hubs include
TNFRSF6, TP53, BIRC2, BIRC3, BCL2, BAX, and CASP1.
Effector caspase-3 is a date hub in both cell types because
intrinsic and extrinsic pathways converge on caspase-3.
Because date hubs appear to be more important than
party hubs [51], caspase-2 and -9 are important date hubs
that differentiate network topologies of cancerous and
normal cells. TP53, BIRC3, BAX, and CASP1 are party
hubs in both cell types. Party hubs are found in static com-
plexes where they interact with most of their partners
simultaneously [51]. In other words, we believe these four
proteins play central roles in functional complexes in
both cancerous and normal cells.
Conclusion
The cancer-perturbed protein-protein interaction net-
works of apoptosis that we developed here shed light on
the mechanism of cancer at the systems level and allow
identification of potential drug targets. In this study, we
applied nonlinear stochastic modeling to describe indi-
vidual and cooperative protein interactions. Our method
is more precise than the linear models used in previous
research. We successfully integrated microarray and pro-
teome databases to identify cancer-perturbed protein-pro-
tein interaction networks. Our predictions of potential
drug targets agreed with potential targets identified by
other studies and also identified additional targets which
may guide the development of new anti-cancer drugs in
future. We also identified static and dynamic hubs inBMC Systems Biology 2008, 2:56 http://www.biomedcentral.com/1752-0509/2/56
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human protein-protein interaction networks, which have
heretofore been identified only in yeast.
Methods
Construction of initial protein-protein interaction 
networks
A comprehensive understanding of protein-protein inter-
actions in an organism provides a framework for under-
standing biology as an integrated system, and human
perturbed protein-protein interaction networks offer
insight into disease mechanisms such as cancer at the sys-
tems level [5,11,25]. Before construction of cancer-per-
turbed protein-protein interaction networks to explore
their roles in the mechanism of cancer, protein-protein
interaction networks for both cancer and normal cells
must be constructed for comparison. The systematic
experimental mappings of the human interactome
include yeast two-hybrid systems [13,14], which reveal
thousands of preys and baits in the protein matrix. Several
online databases such as BIND [15], HPRD [16], Intact
[17], and Himap [18] provide fundamental global topol-
ogies of human protein-protein interactions. The com-
Dynamic protein-protein interactions in caspase formation Figure 4
Dynamic protein-protein interactions in caspase formation. (A) Protein-protein interactions within the hub caspases 
of cancer cells during 0–8 hours after induction of apoptosis. Distinct interactions at different times are marked with bold lines. 
(B) During 4–30 hours after induction of apoptosis in cancer cells. (C) During 0–8 hours after induction of apoptosis in normal 
cells. (D) During 4–36 hours after induction of apoptosis in normal cells (see Supplementary Tables 5 and 6).
A B
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bined use of these databases [15-18] assists precise
estimation of parameters as the basis of construction of
protein-protein interaction networks, because incomplete
rough networks can lead to biased or possibly erroneous
conclusions [11]. We first constructed an initial protein-
protein interaction network using two yeast-two-hybrid
experiments and four online databases.
Studies of large-scale protein-protein interactions allow
development of protein interaction networks, but all
large-scale experiments and databases contain high rates
of false-positives [52]. Previous studies have demon-
strated that use of multiple functional databases allows
better identification of protein-protein interactions and
leads to better prediction of the function of unknown pro-
teins [49]. Therefore, we integrated different databases
and experiments to refine our network [19]. After devel-
opment of our initial network, we used microarray data to
remove false-positive interactions.
Selecting and processing experimental data
We used microarray data [26] to compare gene expression
in HeLa cells and normal primary human lung fibroblasts
subjected to several stresses (e.g., heat shock from 37°C to
42°C, oxidative stress with menadione or hydrogen per-
oxide, and endoplasmic reticulum stress with DTT (dithi-
othreitol) or tunicamycin). Gene expression in HeLa cells
and normal fibroblasts, both of which were treated with
2.5 mM DTT, were our microarray data sources. Gene
expression was recorded at 0–30 h after stress in HeLa cells
and 0–36 h in normal cells [26] (Supplementary Tables 7
and 8; see 'Additional file 7' and 'Additional file 8').
Nonlinear stochastic interaction model of initial networks
We used a nonlinear stochastic model to mimic the
dynamic interactions among proteins to remove false-
positives and refine the network. In recent years, some sys-
tems and computational biologists employ a dynamic
perspective to describe biological functions, because of
their dynamic nature [53-55]. We considered two types of
interactions, binary protein interactions and protein com-
plex interactions, but not DNA-protein or metabolite
interactions. We denote these basal interactions as k in our
model, whereas ε[t] represents stochastic molecular
events, such as molecular fluctuations of the target pro-
tein.
In this study, we define 'individual protein-protein inter-
actions' as binary protein-protein interactions, and 'coop-
erative interactions' as the interaction of a protein
complex with the target protein. x [t] denotes the expres-
sion profile of target protein x at time point t; a denotes
the influence of a target protein at one time point to the
target protein at the next time point; bi denotes individual
or binary interaction of protein i with target protein x [t];
and cij denotes the cooperative interaction ability of pro-
tein i and protein j on the target protein x. Thus, Fig. 5
shows three individual or binary protein-protein interac-
tions to the target protein x [t] (protein x1 [t], x2 [t], and x3
[t]) and one cooperative interaction between protein x1 [t]
and x2 [t] to the target protein x [t]. By consideration of
basal interactions k  and stochastic events ε[t], we can
express the dynamic model of the target protein time pro-
file x [t] as: x [t + 1] = ax [t] +b1x1 [t] +b2x2 [t] + b3x3 [t] +
c12x12 [t] + k + ε [t]. This equation is based on a previously
developed model [56].
Graphical representation of individual protein interactions  and cooperative protein interactions Figure 5
Graphical representation of individual protein inter-
actions and cooperative protein interactions. Our 
dynamic protein interaction equation includes three individ-
ual or binary protein-protein interactions to the target pro-
tein x [t] (protein x1 [t], x2 [t], and x3 [t]) and one cooperative 
interaction between protein x1 [t] and x2 [t] to the target pro-
tein x [t]. a denotes the influence of a target protein at one 
time point to the target protein at the next time point; bi 
denotes individual or binary interaction of protein i with tar-
get protein x [t]; and cij denotes the cooperative interaction 
ability of protein i and protein j on the target protein x.
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Therefore, dynamic interactions between upstream pro-
teins and their targets can be written as:
This equation is based on a previously developed model
[56-58].
Remark: The discrete-time dynamic model in equation (1)
is based on the discrete sampling of the following contin-
uous differential model:
where   denotes the differential of x(t) with
respect to the continuous time t, and λ denotes the decay
rate of x[t]. By unit sampling and with   ≅ x[t + 1] - x[t],
we get the following discrete model [59]:
or
where a denotes the influence of x [t] on x [t +1] and is
dependent of the decay rate, λ.
By iteration of equation (1), we can construct the whole
protein-protein interaction network, which is intercon-
nected through the interactions of   and
 in equation (1) for all proteins. In equation
(1), x [t] represents the expression profile of the target pro-
tein at time point t, which is estimated from mRNA
expression profiles via a translational sigmoid function
[57,58]:
In equation (2), r denotes the transition rate of the sig-
moid function, and M denotes the mean level of mRNA
expression of the corresponding protein.   denotes
all possible individual interactive functions (i.e., all possi-
ble binary protein-protein interactions) of N interactive
protein candidates of the target protein in the initial pro-
tein-protein interaction network, a denotes the influence
of the present target protein on the target protein at the
next time point, and bi indicates the individual interactive
ability of protein i to target protein x [t]. 
denotes all possible interactive functions of cooperative
protein partners with the target protein in the initial net-
work, where xij [t] denotes nonlinear cooperative interac-
tion between protein xi  and protein xj  on the target
protein, that is, xij [t] = f (yi [t]) · f (yj [t]), and cij denotes
the cooperative interaction ability of protein i and protein
j on the target protein (see Fig. 5). We obtained all possi-
ble cooperative interactions   from online
high-throughput protein interaction databases that con-
tained putative protein complexes within the network. If
the multi-protein complex is composed of three or more
proteins, we added all combinations of two cooperative
proteins from the complex to determine the nonlinear
property because one extreme value in the equation will
cause significant aberration in other estimated parame-
ters. The basal interaction k in equation (1) represents
unknown protein-protein interactions that result from
other possible interacting proteins or other influences
(e.g., mRNA-protein interactions, protein synthesis). ε[t]
represents random noise arising from model uncertainty
and molecular fluctuations of protein interactions with
the target protein [24].
With the nonlinear stochastic interaction model (equa-
tion 1), we can identify interaction parameters a, bi, cij and
k using microarray data. After having identified all the
interactions with the target protein, upstream proteins can
be considered as target proteins, and by repeating this pro-
cedure we can identify all interactions of the initial net-
work. If the estimated interaction parameters  ,  , 
and   are not significant according to the AIC, the corre-
sponding interactions will be eliminated from the initial
network.
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Identification of interactions in the initial protein-protein 
interaction network
Before modification of the initial network, we estimated
interaction parameters of the initial network by use of
maximum likelihood estimation. This represents interac-
tions of all possible protein candidates in the initial net-
work. After further rearrangement, equation (1) can be
rewritten as:
where  φ[t] denotes the regression vector composed of
many elements that represent expression levels of protein
candidates in the initial network at time point t.
Employing the cubic spline method [54,58] to interpolate
microarray data allows us to obtain as many data points
as needed. In general, the number of data points should
be at least 5 times the number of parameters to be esti-
mated. The cubic spline method allows us to obtain these
values: {x [t] xi [tl] xj [tl]} for l ∈ {1 2 ... M} and i ∈ {1 2 ...
N}, j ∈ {1 2 ... S}, where M denotes the number of micro-
array data points, N denotes the number of possible pro-
tein interactions for the target protein, and S denotes the
number of protein complexes in the network. These data
points are used as the basis in our regression vector φ[t].
Computation of equation (3) at different time points
allows us to construct the following vector-form equation:
For simplicity, we represent this as:
X = Φ · θ + ν  (5)
In equation (4), random noise ε[tk] is regarded as a white
Gaussian noise with zero mean and unknown variance σ2,
that is, E{ν} = 0, and Σν  =  E{ννT} = σ2I. Next, we
employed a maximum likelihood estimation method
[59] to estimate θ and σ2 using regression data obtained
from the microarray data of the target protein and pro-
teins with which it interacts. Under the assumption that ν
is a Gaussian noise vector with M – 1 elements, its proba-
bility density function is given as follows.
Since ν = X - Φ · θ (equation 5), we can rewrite equation
(6) as:
Maximum likelihood parameter estimation involves find-
ing θ and σ2 to maximize the likelihood function in equa-
tion (7). In order to simplify the computation, it is
practical to take the logarithm of equation (7), which
yields the following log-likelihood function:
In equation (8), x [tk] and φ[tk] are the kth elements of X
and Φ respectively.
Here, we expect the log-likelihood function to have the
maxima at θ =   and  σ2 =  . The necessary conditions
for determining maximum likelihood estimates   and
 must consist of [59]:
After some computational arrangements from equation
(9), the estimated parameters   and   are:
After obtaining estimate  , we can rewrite estimated pro-
tein-protein interaction (equation 1) as follows:
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We quantified the interactions of all candidate proteins by
the process described above.
In equation (12), the estimated parameter   denotes the
estimation of the residual of target protein,   denotes
individual interactive rate or binary protein-protein inter-
action between protein i and the target protein, and 
denotes cooperative interactive rate or protein complex
membership between protein i and protein j, i.e. protein
complex ij, to the target protein. A positive value implies
positive interaction, a negative value implies negative
interaction, and the interactions are more likely as the
parameters get larger.
Modification of initial protein-protein interaction 
networks
Although our maximum likelihood estimation method
allows quantification of all possible interactions of a tar-
get protein, we still do not know the significance of the
interaction and whether it can be regarded as a true inter-
action. Thus, we used a statistical approach that involves
model validation to evaluate significance levels and refine
the network. In this procedure, we employed the Akaike
Information Criterion (AIC) to validate the model order
or the number of model parameters of the network [59].
The Akaike Information Criterion (AIC) considers esti-
mated residual variance and model complexity as one sta-
tistic and provides a measure of the information lost when
a model is used. In other words, the AIC is an operational
way of trading off the complexity of an estimated model
against how well the model fits the data. AIC decreases as
residual variance   decreases and increases as the
number of parameters p increases. As the expected resid-
ual variance decreases with increasing P for inadequate
model complexities, there should be a minimum near the
correct number of interaction parameters P. For a protein
interaction model with P  interaction parameters to fit
with data from N samples, the Akaike Information Crite-
rion (AIC) can be written as follows [59]
where   denotes the estimated expression profile of the
target protein, i.e.   = φ ·  . After the statistical selection
of P parameters by minimizing the AIC, we can determine
whether the protein interaction is significant or a false
positive.
In our results, '1' represents protein i interacting with pro-
tein j if the interaction is within P significant interactions,
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Table 2: Truth table of all 16 events in the sample space of comparisons of individual interaction of protein i and protein j between 
HeLa and normal cells
AIC detection results in HeLa cells AIC detection results in normal cells Comparisons between HeLa and normal 
cells
Target protein i Target protein j 'AND' results Target protein i Target protein j 'AND' results
0 000 00
0 000 10
0 001 00
0 001 11 L o s s - o f - f u n c t i o n
0 100 00
0 100 10
0 101 00
0 101 11 L o s s - o f - f u n c t i o n
1 000 00
1 000 10
1 001 00
1 001 11 L o s s - o f - f u n c t i o n
1 1 1 0 0 0 Gain-of-function
1 1 1 0 1 0 Gain-of-function
1 1 1 1 0 0 Gain-of-function
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and '0' represents protein i not interacting with protein j if
the interaction has less than P significant interactions. It
must be considered that protein-protein interaction net-
works represent mutual binding relationships; if protein i
binds to protein j, then protein j also binds to protein i. To
determine mutual relationships in the high false positive
yeast-two-hybrid experiments, we use the Boolean logical
'AND' to determine the interaction maps. Two proteins
were considered to interact only if each protein binds to
the other protein (see Supplementary Table 1). If an inter-
action is detected only in HeLa cells but not in normal
cells, we call this a 'gain-of-function'; if the interaction is
detected in normal cells but not HeLa cells, we call it a
'loss-of-function'. Table 2 shows the truth table of all 16
events in the sample space of comparisons of individual
protein-protein interactions between HeLa cells and nor-
mal cells, as determined with our AIC detection algo-
rithm. Protein complexes are only considered once,
because of incomplete information from online data-
bases. We iteratively refined interactions in the initial net-
work using a similar procedure. Finally, this yielded a
refined protein-protein interaction network for HeLa and
normal cells.
We provide all Matlab programs and codes of these figures
drawn by Osprey 1.2.0 [60] in 'Additional file 9' and
'Additional file 10'. In the Matlab programs, we consider
the target protein BAX as an example. Readers can simu-
late other target proteins using a similar procedure.
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